OncoMatch/Clinical Trials/NCT06915246
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
Is NCT06915246 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including VI-0609 and BiCNU for lymphoma.
Treatment: VI-0609 · BiCNU — A phase 2 multicenter study of VI-0609 vs BiCNU in the BEAM high-intensity conditioning regimen for AHCT in subjects with lymphomas.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Hodgkin Lymphoma
Prior therapy
Must have received: salvage cytoreductive chemotherapy
Recovery from non-hematologic toxicities of salvage cytoreductive chemotherapy to ≤ grade 2
Cannot have received: high-dose chemotherapy with autologous stem cell transplant
Prior high-dose chemotherapy with autologous stem cell transplant
Cannot have received: allogeneic transplantation
prior allogeneic transplantation
Cannot have received: external beam radiation therapy
Exception: dose-limiting radiation to a critical organ
Significant prior external beam dose-limiting radiation to a critical organ
Lab requirements
Cardiac function
lvef ≥ 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Phoenix · Goodyear, Arizona
- City of Hope National Medical Center · Duarte, California
- City of Hope Atlanta · Newnan, Georgia
- City of Hope Chicago · Zion, Illinois
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06915246 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior high-dose chemotherapy with autologous stem cell transplant, allogeneic transplantation, external beam radiation therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages